{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T04:13:00Z","timestamp":1771647180618,"version":"3.50.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.juro.2011.04.070","type":"journal-article","created":{"date-parts":[[2011,7,27]],"date-time":"2011-07-27T01:02:06Z","timestamp":1311728526000},"page":"877-881","source":"Crossref","is-referenced-by-count":41,"title":["Integrated Safety Data From 4 Randomized, Double-Blind, Controlled Trials of Autologous Cellular Immunotherapy With Sipuleucel-T in Patients With Prostate Cancer"],"prefix":"10.1097","volume":"186","author":[{"given":"Simon J.","family":"Hall","sequence":"first","affiliation":[{"name":"Mount Sinai School of Medicine, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Klotz","sequence":"additional","affiliation":[{"name":"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan J.","family":"Pantuck","sequence":"additional","affiliation":[{"name":"University of California-Los Angeles, Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"George","sequence":"additional","affiliation":[{"name":"Duke University, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B.","family":"Whitmore","sequence":"additional","affiliation":[{"name":"Dendreon Corp., Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark W.","family":"Frohlich","sequence":"additional","affiliation":[{"name":"Dendreon Corp., Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert B.","family":"Sims","sequence":"additional","affiliation":[{"name":"Dendreon Corp., Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2011.04.070_bib1","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.juro.2011.04.070_bib2","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2011.04.070_bib3","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1200\/JCO.1999.17.8.2506","article-title":"Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study","volume":"17","author":"Kantoff","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2011.04.070_bib4","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2011.04.070_bib5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1016\/j.juro.2011.04.070_bib6","article-title":"Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC)","volume":"25","author":"Beer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2011.04.070_bib7","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/cncr.24429","article-title":"Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer","volume":"115","author":"Higano","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2011.04.070_bib8","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2011.04.070_bib9","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1200\/JCO.2000.18.23.3894","article-title":"Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells","volume":"18","author":"Small","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2011.04.070_bib10","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1056\/NEJMe0807372","article-title":"Identifying and addressing safety signals in clinical trials","volume":"359","author":"Fleming","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2011.04.070_bib11","series-title":"Reviewer Guidance: Conducting a Clinical Safety Review on a New Product Application and Preparing a Report on the Review","year":"2005"},{"key":"10.1016\/j.juro.2011.04.070_bib13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1023\/A:1006341717398","article-title":"Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy","volume":"18","author":"Dillman","year":"1999","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.juro.2011.04.070_bib14","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2000.18.12.2444","article-title":"High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690\/S9111\/C9190","volume":"18","author":"Kirkwood","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2011.04.070_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1586\/eci.10.90","article-title":"Acute infusion reactions induced by monoclonal antibody therapy","volume":"7","author":"Maggi","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.juro.2011.04.070_bib16","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00262-008-0474-9","article-title":"CD54 is a surrogate marker of antigen presenting cell activation","volume":"57","author":"Sheikh","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.juro.2011.04.070_bib17","series-title":"Molecular Biology of the Cell","author":"Alberts","year":"2005"},{"key":"10.1016\/j.juro.2011.04.070_bib18","series-title":"FDA Clinical Briefing Document for the Oncologic Drug Advisory Committee September 13, 2005 Meeting","author":"Ibrahim","year":"2005"},{"key":"10.1016\/j.juro.2011.04.070_bib19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.canlet.2005.05.021","article-title":"Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues","volume":"236","author":"Cunha","year":"2006","journal-title":"Cancer Lett"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534711038511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534711038511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2011.04.070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T02:18:49Z","timestamp":1651198729000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2011.04.070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1016\/j.juro.2011.04.070"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2011.04.070","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}